Lundbeck's hopes have high costs: "You won't see us reaching that level in the future"

Pharmaceutical company Lundbeck has upgraded its R&D expenses due to high stakes on migraine drug Vyepti. The level is unnaturally high but will fluctuate in the future, says head of R&D.

Photo: Jens Dresling

In the last year, Denmark's second-largest pharmaceutical company, Lundbeck, has upgraded its expenses for research and development, not least due to its major stakes on turning migraine drug Vyepti into a blockbuster.

Thus, Lundbeck placed more than 25 percent of its revenue in research and development investments, while the concurrent figure for Novo Nordisk was around half of that in the same time period.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs